TherapeuticsMD, Inc. Net Cash Provided by (Used in) Discontinued Operations
TherapeuticsMD, Inc. (TXMD) reported Net Cash Provided by (Used in) Discontinued Operations of -$17.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:NetCashProvidedByUsedInDiscontinuedOperations · last filed 2026-08-11
- TherapeuticsMD, Inc. net cash provided by (used in) discontinued operations for the quarter ending 2026-06-30 was -$9.00K.
- TherapeuticsMD, Inc. net cash provided by (used in) discontinued operations for the quarter ending 2026-03-31 was -$8.00K.
- TherapeuticsMD, Inc. net cash provided by (used in) discontinued operations for the quarter ending 2025-12-31 was -$7.00K.
- TherapeuticsMD, Inc. net cash provided by (used in) discontinued operations for the quarter ending 2025-09-30 was $47.00K.
- TherapeuticsMD, Inc. net cash provided by (used in) discontinued operations for fiscal 2025 was -$30.00K.
- TherapeuticsMD, Inc. net cash provided by (used in) discontinued operations for fiscal 2024 was -$438.00K.
- TherapeuticsMD, Inc. net cash provided by (used in) discontinued operations for fiscal 2023 was -$25.06M, a 111.91% decline from fiscal 2022.
- TherapeuticsMD, Inc. net cash provided by (used in) discontinued operations for fiscal 2022 was $210.40M.
| Period end | Net Cash Provided by (Used in) Discontinued Operations 3 month | Net Cash Provided by (Used in) Discontinued Operations 6 month | Net Cash Provided by (Used in) Discontinued Operations 9 month | Net Cash Provided by (Used in) Discontinued Operations 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$9.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$17.00K 10-Q · filed 2026-08-11 | -$24.00K derived: sum of 3 quarters · filed 2026-08-11 | $23.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$8.00K 10-Q · filed 2026-05-12 | -$15.00K derived: sum of 2 quarters · filed 2026-05-12 | $32.00K derived: sum of 3 quarters · filed 2026-05-12 | -$25.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$7.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2026-04-01 | $40.00K derived: sum of 2 quarters · filed 2026-04-01 | -$17.00K derived: sum of 3 quarters · filed 2026-08-11 | -$30.00K 10-K/A · filed 2026-04-01 |
| 2025-09-30 | $47.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$10.00K derived: sum of 2 quarters · filed 2026-08-11 | -$23.00K 10-Q · filed 2025-11-12 | -$28.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$57.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$70.00K 10-Q · filed 2026-08-11 | -$75.00K derived: sum of 3 quarters · filed 2026-08-11 | -$189.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$13.00K 10-Q · filed 2026-05-12 | -$18.00K derived: sum of 2 quarters · filed 2026-05-12 | -$132.00K derived: sum of 3 quarters · filed 2026-05-12 | -$691.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$5.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2026-04-01 | -$119.00K derived: sum of 2 quarters · filed 2026-04-01 | -$678.00K derived: sum of 3 quarters · filed 2026-04-01 | -$438.00K 10-K/A · filed 2026-04-01 |
| 2024-09-30 | -$114.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$673.00K derived: sum of 2 quarters · filed 2025-11-12 | -$433.00K 10-Q · filed 2025-11-12 | -$3.31M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$559.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$319.00K 10-Q · filed 2025-08-12 | -$3.20M derived: sum of 3 quarters · filed 2025-08-12 | -$734.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $240.00K 10-Q · filed 2025-05-13 | -$2.64M derived: sum of 2 quarters · filed 2025-05-13 | -$175.00K derived: sum of 3 quarters · filed 2025-05-13 | -$1.45M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$2.88M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$415.00K derived: sum of 2 quarters · filed 2025-03-27 | -$1.69M derived: sum of 3 quarters · filed 2025-03-27 | -$25.06M 10-K · filed 2025-03-27 |
| 2023-09-30 | $2.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $1.19M derived: sum of 2 quarters · filed 2024-08-12 | -$22.18M 10-Q · filed 2023-11-14 | $70.59M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-06-30 | -$1.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$24.64M 10-Q · filed 2024-08-12 | $68.13M derived: sum of 3 quarters · filed 2024-08-12 | $60.69M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | -$23.37M 10-Q · filed 2023-05-15 | $69.40M derived: sum of 2 quarters · filed 2024-03-29 | $61.97M derived: sum of 3 quarters · filed 2024-03-29 | $198.68M derived: sum of 4 quarters · filed 2024-03-29 |
| 2022-12-31 | $92.77M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $85.33M derived: sum of 2 quarters · filed 2024-03-29 | $222.05M derived: sum of 3 quarters · filed 2024-03-29 | $210.40M 10-K · filed 2024-03-29 |
| 2022-09-30 | -$7.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $129.28M derived: sum of 2 quarters · filed 2023-11-14 | $117.63M 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $136.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $125.06M 10-Q · filed 2023-08-14 | ||
| 2022-03-31 | -$11.65M 10-Q · filed 2023-05-15 | |||
| 2021-12-31 | -$87.56M 10-K · filed 2023-04-07 | |||
| 2011-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-07 | $50.16K 10-Q · filed 2011-11-07 | ||
| 2011-06-30 | $50.16K 10-Q · filed 2011-08-15 | |||
| 2010-09-30 | -$391.26K derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-07 | -$6.82K 10-Q · filed 2011-11-07 | ||
| 2010-06-30 | $384.44K 10-Q · filed 2011-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |